[
  {
    "ts": null,
    "headline": "Big Pharma's Earnings Week: Strong Performance, Obesity Wars, LOE Management And More",
    "summary": "Big pharma Q4 2025 beats: Lilly leads obesity/diabetes, Novo faces 2026 pressure, LOE transitions in focus.",
    "url": "https://finnhub.io/api/news?id=f8944b09b7fd83e5420be2f4af05b504c53449ae617b3594f5665404d55c833d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770453000,
      "headline": "Big Pharma's Earnings Week: Strong Performance, Obesity Wars, LOE Management And More",
      "id": 138384854,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2154390775/image_2154390775.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Big pharma Q4 2025 beats: Lilly leads obesity/diabetes, Novo faces 2026 pressure, LOE transitions in focus.",
      "url": "https://finnhub.io/api/news?id=f8944b09b7fd83e5420be2f4af05b504c53449ae617b3594f5665404d55c833d"
    }
  }
]